New Triple-Drug attack shows promise for Hard-to-Treat breast cancer
Disease control
Recruiting now
This study is for people with a type of advanced breast cancer called HR+/HER2-negative. It tests a new drug, VS-6766, combined with two standard drugs (abemaciclib and fulvestrant). The goal is to find the safest dose and see if the combination can shrink tumors or stop them fro…
Phase: PHASE1, PHASE2 • Sponsor: Adrienne G. Waks • Aim: Disease control
Last updated Jun 27, 2026 12:26 UTC